Metabolic Characteristics of Sarcoma In Vivo Using HP 13-C Magnetic Resonance Spectroscopic Imaging (MRSI)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2019-01-01

Study Completion Date

2021-08-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Investigators will determine whether MRSI using hyperpolarized \[1-13C\]pyruvate provide useful information of tumor malignancy in MRI-indeterminate cases. Metabolite maps of hyperpolarized \[1-13C\]lactate and H13CO3- produced from hyperpolarized \[1-13C\]pyruvate will be compared to the biopsy results of MRI-indeterminate patients and the 13C-maps of age-matched healthy subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Mitochondrial Respiratory Function in Mammalian Skeletal Muscle

NCT02650570

Cancer Cachexia

TERMINATED

13C Pyruvate DNP MR Spectroscopy for Lymphoma Treatment Response Assessment

NCT05600361

Patient Outcome Assessment

UNKNOWN NA

Quantitative MR Biomarkers for Sarcoma Treatment

NCT01017978

Soft Tissue Tumors

COMPLETED NA

Identification and Characterization of Molecular Markers in Musculoskeletal Tumors

NCT02199938

Soft Tissue and Bone Tumors Sarcoma Sarcoma of Bone +1 more

TERMINATED

Intravital Microscopy in Human Solid Tumors

NCT03823144

Solid Tumor, Adult Clinical Stage IV Gastric Cancer AJCC v8 Malignant Solid Neoplasm +20 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

A non-randomized, interventional (nontherapeutic), feasibility trial to detect metabolic changes in participants with musculoskeletal sarcoma using hyperpolarized \[1-13C\]pyruvate Magnetic Resonance Spectroscopy Imaging (MRSI). All measured quantities will be tabulated and the analysis will be descriptive and obervational in nature.

Participants in this study will receive the study drug, hyperpolarized \[1-13C\]pyruvate, as a bolus injection during an MRSI of either a soft tissue sarcoma or healthy tissue. After the study drug injection and MRSI, participants will then receive contrast material, Gadavist, via injection during continuation the MRI.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Sarcoma, Soft Tissue

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hyperpolarized 13CPyruvate and gadolinium

Injection with hyperpolarized 13CPyruvate followed by gadolinium during MRSI.

Hyperpolarized 13CPyruvate

Intervention Type DRUG

Bolus injection of study drug during MRSI.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Hyperpolarized 13CPyruvate

Bolus injection of study drug during MRSI.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

HP Pyruvate injection

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

SARCOMA patients:

\- MRI indeterminate solid enhancing lesion in the pelvis or extremity.

ALL subjects:

* Age 18 through 100 years.
* Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry, for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately.
* Ability to understand and the willingness to sign a written informed consent.
* All races and ethnicities will be included; subjects must be able to read and speak the English or Spanish language.

Exclusion Criteria

SARCOMA patients:

-Subjects who have had radiotherapy to the indeterminate lesion.

ALL subjects:

* Subjects who have had chemotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier.
* Subjects may not be receiving any other investigational agents.
* Any contraindication per MRI Screening form including implants contraindicated at 3T, pacemakers, implantable Cardioverter Defibrillator (ICD), claustrophobia.
* Metallic foreign bodies in the field of view which may interfere with MRI acquisitions.
* Since each subject is receiving a gadolinium based contrast agent intravenously, additional contraindications would include: eGFR ≤ 30 mL/min/1.73m2, sickle cell disease, or hemolytic anemia.
* Uncontrolled psychiatric illness/social situations that would limit compliance with study requirements.
* Subjects must not be pregnant or nursing due to the potential for congenital abnormalities and the potential of this regimen to harm nursing infants.

Minimum Eligible Age

18 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes